Aurobindo Pharma’s fund-raising plans

| Updated on January 22, 2018 Published on November 18, 2015


Aurobindo Pharma will seek approval from its shareholders for an enabling resolution to raise up to $600 million (about ₹3,980 crore). In January, its shareholders had approved a $350-million QIP issue but the company did not raise the funds due to volatile market.

The resolution had a validity period of one year. Hence, the board is again seeking shareholders’ nod for the revised amount, proposed to be raised either through FCCBs, ADRs, GDRs, QIP or QFIs.

Published on November 18, 2015
This article is closed for comments.
Please Email the Editor